Hitachi Chemical Advanced Therapeutics Solutions (HCATS), a U.S. subsidiary of Hitachi Chemical Co., Ltd. that engages in contract manufacturing and manufacturing development of cell therapy products, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing, have entered into a joint development agreement to develop and commercialize technology solutions specific to the CGT industry. Robert Preti, president and chief executive officer, HCATS, said, “Combining HCATS’ ex...